Beyond Air, Inc. (NASDAQ:XAIR – Get Free Report) traded up 3.2% during trading on Thursday . The company traded as high as $1.74 and last traded at $1.63. 179,722 shares were traded during trading, a decline of 43% from the average session volume of 314,859 shares. The stock had previously closed at $1.58.
Beyond Air Stock Up 3.2 %
The firm has a market cap of $58.75 million, a price-to-earnings ratio of -0.77 and a beta of -0.18. The business’s 50 day moving average price is $1.75 and its 200 day moving average price is $1.88. The company has a debt-to-equity ratio of 0.61, a quick ratio of 3.26 and a current ratio of 3.39.
Beyond Air (NASDAQ:XAIR – Get Free Report) last released its quarterly earnings results on Monday, February 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.11. The company had revenue of $0.39 million during the quarter, compared to analyst estimates of $0.49 million. During the same period in the prior year, the business posted ($0.43) EPS. On average, equities analysts forecast that Beyond Air, Inc. will post -1.93 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in XAIR. Wexford Capital LP purchased a new position in Beyond Air in the 4th quarter valued at $26,000. UBS Group AG purchased a new position in shares of Beyond Air during the 1st quarter worth $30,000. Keel Point LLC purchased a new position in shares of Beyond Air during the 4th quarter worth $30,000. Scotia Capital Inc. purchased a new position in shares of Beyond Air during the 3rd quarter worth $31,000. Finally, California State Teachers Retirement System purchased a new position in shares of Beyond Air during the 2nd quarter worth $36,000. Hedge funds and other institutional investors own 31.50% of the company’s stock.
About Beyond Air
Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.